Next-gen T cell player TCR2 Therapeutics sets stage for $100M-plus IPO as MPM's Baeuerle caps prolific year
Patrick Baeuerle has been busy. Right after steering next-gen BiTE company Harpoon Therapeutics toward an IPO, the MPM partner and immunologist is shepherding another …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.